All In Biotech

Free tool

FAERS Monitor: Nuedexta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021879 or its brand name (Nuedexta, Dextromethorphan Hydrobromide, Quinidine Sulfate). Reports on generic versions are filed under their own applications.

Reports

3,631

Serious

1,230

34% of reports

Hospitalization

502

Death reported

282

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fall208
  • off label use208
  • product use in unapproved indication195
  • death192
  • drug ineffective192
  • dizziness169
  • therapy interrupted161
  • fatigue145
  • diarrhoea135
  • nausea111
  • somnolence104
  • dysphagia102
  • inability to afford medication101
  • gait disturbance97
  • condition aggravated96

Reports by year received

View as table
YearReports
201116
201233
201338
201473
2015559
2016518
2017414
2018368
2019331
2020244
2021190
2022122
2023212
2024264
2025201
202648

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,528 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
inability to afford medicationSignal10159.549.05,696
therapy interruptedSignal16113.111.21,786
dysphagiaSignal1026.25.1444
product use in unapproved indicationSignal1954.64.0544
fallSignal2083.63.2398
somnolenceSignal1043.02.5137
gait disturbanceSignal972.92.4123
dizziness1692.01.781
condition aggravated961.81.536
off label use2081.41.222
death1921.31.113
diarrhoea1351.21.05
fatigue1451.10.91
drug ineffective1920.80.76
nausea1110.80.75

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.